IRGM rs13361189 polymorphism may contribute to susceptibility to Crohn's disease: A meta-analysis

  • Authors:
    • Yao Lu
    • Chun-Yu Li
    • Shu-Sen Lin
    • Peng Yuan
  • View Affiliations

  • Published online on: May 28, 2014     https://doi.org/10.3892/etm.2014.1736
  • Pages: 607-613
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present meta‑analysis was to evaluate the correlation between a common polymorphism, rs13361189 C>T in the immunity‑related GTPase M (IRGM) gene, and susceptibility to Crohn's disease (CD). The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library and CBM databases were investigated from database inception through to October 1, 2013 without the application of any language restrictions. The meta‑analysis was performed using STATA 12.0 software and the relative risk (RR) with a 95% confidence interval (CI) was calculated. Seven case‑control studies were included with a total of 3,093 CD patients and 3,227 healthy control subjects. The results of the meta‑analysis revealed that the IRGM rs13361189 polymorphism correlates with an increased risk of CD (T allele versus C allele: RR=1.25 with 95% CI, 1.04‑1.50; P=0.016 and CT + TT versus CC: RR=1.21 with 95% CI, 1.03‑1.42; P=0.018). A subgroup analysis conducted using a genotyping method indicated that the IRGM rs13361189 polymorphism was correlated with an increased risk of CD in the TaqMan® (T allele versus C allele: RR=1.32 with 95% CI, 1.01‑1.73; P=0.042) and the polymerase chain reaction‑restriction fragment length polymorphism subgroups (T allele versus C allele: RR=1.80 with 95% CI, 1.32‑2.45; P<0.001 and CT + TT versus CC: RR=1.61 with 95% CI, 1.19‑2.18; P=0.018). However, no correlation was observed in the direct sequencing subgroup (P>0.05). Further subgroup analysis by sample size demonstrated significant correlations between the IRGM rs13361189 polymorphism and an increased risk of CD in the large sample‑size subgroup (T allele versus C allele: RR=1.46 with 95% CI, 1.26‑1.68; P<0.001 and CT + TT versus CC: RR=1.40 with 95% CI, 1.21‑1.62; P<0.001). However, no correlation was identified between the IRGM rs13361189 polymorphism and CD risk in the small sample‑size subgroup (P>0.05). The present meta‑analysis indicated that the IRGM rs13361189 polymorphism may contribute to susceptibility to CD. Thus, IRGM rs13361189 polymorphism may be a potential biomarker for the early diagnosis of CD.
View Figures
View References

Related Articles

Journal Cover

August-2014
Volume 8 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu Y, Li C, Lin S and Yuan P: IRGM rs13361189 polymorphism may contribute to susceptibility to Crohn's disease: A meta-analysis. Exp Ther Med 8: 607-613, 2014
APA
Lu, Y., Li, C., Lin, S., & Yuan, P. (2014). IRGM rs13361189 polymorphism may contribute to susceptibility to Crohn's disease: A meta-analysis. Experimental and Therapeutic Medicine, 8, 607-613. https://doi.org/10.3892/etm.2014.1736
MLA
Lu, Y., Li, C., Lin, S., Yuan, P."IRGM rs13361189 polymorphism may contribute to susceptibility to Crohn's disease: A meta-analysis". Experimental and Therapeutic Medicine 8.2 (2014): 607-613.
Chicago
Lu, Y., Li, C., Lin, S., Yuan, P."IRGM rs13361189 polymorphism may contribute to susceptibility to Crohn's disease: A meta-analysis". Experimental and Therapeutic Medicine 8, no. 2 (2014): 607-613. https://doi.org/10.3892/etm.2014.1736